Bespoke Extracts (BSPK) 10-Q 16 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 16, 2022
Document Information Line Items
Entity Registrant Name	BESPOKE EXTRACTS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		417,131,119
Amendment Flag	false
Entity Central Index Key	0001409197
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-52759
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	20-4743354
Entity Address, Address Line One	2590 Walnut St
Entity Address, City or Town	Denver
Entity Address, Country	CO
Entity Address, Postal Zip Code	80205
Local Phone Number	633-3738
City Area Code	855
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 94,331	$ 148,227
Accounts receivable, net	3,700	3,636
Advances to WonderLeaf	6,443
Note receivable and accrued interest WonderLeaf	20,181
Prepaid expense	5,443	6,439
Inventory, net	46,470	46,825
Total current assets	176,568	205,127
Furniture and equipment	9,947	2,745
Right of Use Asset	324,035	339,780
Deposits	12,000	12,000
Total assets	522,550	559,652
Current liabilities
Accounts payable and accrued liabilities	105,621	82,729
Inventory earn-out	75,000	75,000
Note payable - related party		2,500
Operating lease liability	61,279	59,777
Total current liabilities	241,900	220,006
Long-Term Operating Lease Liability	264,219	280,369
Total liabilities	506,119	500,375
Commitments and contingencies (Note 10)
Stockholders’ Equity
Preferred stock, par value $0.001, 50,000,000 shares authorized, 1 share issued and outstanding as of March 31, 2022 and December 31, 2021, respectively
Series C Preferred Stock, $0.001 par value, 1 share designated; 1 share issued and outstanding as of March 31, 2022 and December 31, 2021, respectively, stated value $24,000
Common stock, $0.001 par value: 3,000,000,000 shares authorized; 406,129,924 and 366,679,924 shares issued and 338,629,924 and 299,179,924 shares outstanding as of March 31, 2022 and December 31, 2021, respectively	338,630	299,180
Additional paid-in capital	20,417,867	19,527,669
Accumulated deficit	(20,740,066)	(19,767,572)
Total stockholders’ equity	16,431	59,277
Total liabilities and stockholders’ equity	$ 522,550	$ 559,652

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, share issued	1	1
Preferred stock, share outstanding	1	1
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	406,129,924	366,679,924
Common stock, shares outstanding	338,629,924	299,179,924
Series C Preferred Stock
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, share issued	1	1
Preferred stock, share outstanding	1	1
Preferred stock, designated share	1	1
Preferred stock, share stated value (in Dollars)	$ 24,000	$ 24,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Sales	$ 3,061	$ 5,748
Cost of products sold	847	1,368
Gross Profit	2,214	4,380
Operating expenses:
Selling, general and administrative expenses	897,534	191,861
Professional fees	54,355	21,343
Consulting	23,000	71,500
Amortization expense of domain name		811
Total operating expenses	974,889	285,515
Loss from operations	(972,675)	(281,135)
Other income
Interest income	181
Total other income	181
Loss before income tax	(972,494)	(281,135)
Provision for income tax
Net Loss	$ (972,494)	$ (281,135)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and Diluted (in Shares)	314,643,146	240,532,826
NET LOSS PER COMMON SHARE OUTSTANDING
Basic and Diluted (in Dollars per share)	$ 0	$ 0

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders Equity / (Deficit) (Unaudited) - USD ($)	Series CPreferred Shares	Common Shares	Additional Paid-in Capital	Common Stock Payable	Accumulated Deficit	Total
Balance at Dec. 31, 2020		$ 229,389	$ 18,307,635	$ 76,000	$ (19,115,950)	$ (502,926)
Balance (in Shares) at Dec. 31, 2020	1	229,388,426
Common stock for conversion of note payable - related party		$ 5,000	95,000			100,000
Common stock for conversion of note payable - related party (in Shares)		5,000,000
Sale of common stock		$ 12,000	588,000			600,000
Sale of common stock (in Shares)		12,000,000
Issuance of common stock payable		$ 500	75,500	(76,000)
Issuance of common stock payable (in Shares)		500,000
Net loss					(281,135)	(281,135)
Balance at Mar. 31, 2021		$ 246,889	19,066,135		(19,397,085)	(84,061)
Balance (in Shares) at Mar. 31, 2021	1	246,888,426
Balance at Dec. 31, 2021		$ 299,180	19,527,669		(19,767,572)	59,277
Balance (in Shares) at Dec. 31, 2021	1	299,179,924
Payment of capital contribution			4,792			4,792
Stock based compensation and stock option expense			727,606			727,606
Unit Offering		$ 39,450	157,800			197,250
Unit Offering (in Shares)		39,450,000
Net loss					(972,494)	(972,494)
Balance at Mar. 31, 2022		$ 338,630	$ 20,417,867		$ (20,740,066)	$ 16,431
Balance (in Shares) at Mar. 31, 2022	1	338,629,924

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net Loss	$ (972,494)	$ (281,135)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization expense of domain names		811
Amortization of Right of Use Asset	15,745	3,061
Stock based compensation and stock option expense	727,606
Changes in operating assets and liabilities:
Accounts receivable	(64)	(1,230)
Prepaid expense	996	(80,661)
Inventory	355	(6,207)
Interest receivable WonderLeaf	(181)
Operating lease liability	(14,648)
Accounts payable and accrued liabilities	22,892	29,862
Net Cash used in operating activities	(219,793)	(335,499)
Cash flows from investing activities
Advances to WonderLeaf	(6,443)
Payments to Note receivable WonderLeaf	(20,000)
Purchase of equipment	(7,202)
Net cash used in investing activities	(33,645)
Cash flow from financing activities
Payment of capital contribution	4,792
Repayment of note payable - related party	(2,500)
Proceeds from the issuance of units	197,250	600,000
Net cash provided by financing activities	199,542	600,000
Net increase / (decrease) in cash	(53,896)	264,501
Cash at beginning of period	148,227	79,795
Cash at end of period	94,331	344,296
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for income taxes
Noncash investing and financing activities:
Stock issued for conversion of debt - related party		$ 100,000

Nature of Operations, Significa

Nature of Operations, Significant Accounting Policies and Going Concern	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN	1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN Nature of Business Operations Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products. In November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United States. On December 2, 2021, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”), a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the WonderLeaf Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement. As of the date of filing the Company has not closed on the transaction. Basis of Presentation The accompanying condensed consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2022. For further information, refer to the Company’s financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2021 and the Transition Report on Form 10Q-T for the transition period from September 1, 2021 to December 31, 2021. On February 2, 2022, the Company changed its fiscal year from August 31 to December 31. Certain prior period amounts have been reclassified to conform to the current period presentation. Principles of Consolidation The accompanying condensed consolidated unaudited financial statements include the accounts of Bespoke Extracts, Inc., and its wholly owned subsidiary Bespoke Extracts Colorado, LLC. All inter-company balances have been eliminated. Going Concern The accompanying condensed consolidated unaudited financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit as of and for the three months ended March 31, 2022. This raises substantial doubt about our ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At March 31, 2022 and December 31, 2021, the Company did not have any cash equivalents. Fair Value of Financial Instruments The carrying amounts of cash, accounts receivable, prepaid expenses, inventory and other assets, accounts payable, accrued liabilities, note payable and convertible note payable approximate their fair values as of March 31, 2022 and December 31, 2021, respectively, because of their short-term natures and the Company’s borrowing rate of interest. Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At March 31, 2022 and December 31, 2021, the Company has recorded an allowance for doubtful accounts of $0 and $0, respectively. At March 31, 2022 and December 31, 2021 included in the accounts receivable is the merchant holdback receivable balance of $3,636 and $3,636, respectively which will be remitted to the Company in the future. Advances to WonderLeaf During the three months ended March 31, 2022 the Company advanced WonderLeaf $6,443 to cover operating expenses. The amounts are repayable upon demand. Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of March 31, 2022 and December 31, 2021, inventory amounted to $46,470 and $46,825, respectively, which consisted of finished goods of $43,219 and $43,574, and raw materials of $3,251 and $3,251 net of reserves, respectively. As of March 31, 2022 and December 31, 2021 inventory reserves were $33,476 and $33,476, respectively. Revenue Recognition We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 30 day return policy on sales. Stock Based Compensation Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance with FASB ASC 718 , Compensation-Stock Compensation, Net Income / (Loss) per Share Basic income / (loss) per share amounts are computed based on net income / (loss) divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 25,333,500 warrants and 46,072,874 options is anti-dilutive for the three months ended March 31, 2022 as they are not in the money. The effect of 3,000,000 warrants and 0 options, as well as 500,000,000 shares issuable upon the conversion of a convertible note, is anti-dilutive for the three months ended March 31, 2021. Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Income Taxes We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

Asset Purchase Agreement

Asset Purchase Agreement	3 Months Ended
	Mar. 31, 2022
Asset Purchase Agreement [Abstract]
ASSET PURCHASE AGREEMENT	2. ASSET PURCHASE AGREEMENT On February 21, 2017, the Company purchased all right, title, interest and goodwill in or associated with certain domain names set forth in an asset purchase agreement for a total of $20,185 in cash and 200,000 shares of the Company’s common stock valued at $30,000. During the year ended August 31, 2020, the Company transferred certain URLs valued at $5,282 to an unrelated party and impaired $289 leaving a balance of $44,614 of URLs. The domain names are being amortized over a 15 year period. During the year ended August 31, 2021, the Company recorded an amortization expense of $3,244. During the year ended August 31, 2020, the Company recorded an impairment expense of $289 for the expired domain names. During the three months ended March 31, 2022 and 2021, the Company recorded an amortization expense of $0 and $811, respectively. In connection with a stock purchase agreement (see note 7), on October 28, 2021, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto, dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4 thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder. In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names valued at $32,748. (See Notes 3 and 6.)

Inventory Earn-Out

Inventory Earn-Out	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY EARN-OUT	3. INVENTORY EARN-OUT As described in Notes 2 and 6, in exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company, and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. As of March 31, 2022 no amounts have been paid.

Note Receivable

Note Receivable	3 Months Ended
	Mar. 31, 2022
Receivables [Abstract]
NOTE RECEIVABLE	4. NOTE RECEIVABLE On January 19, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5.0% annually and matures on January 18, 2023. Accrued interest amounted to $111 at March 31, 2022. On February 8, 2022 the Company loaned WonderLeaf $10,000, pursuant to a promissory note. The note bears interest at 5.0% annually and matures on February 8, 2023. Accrued interest amounted to $70 at March 31, 2022.

Note Payable - Related Party

Note Payable - Related Party	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
NOTE PAYABLE - RELATED PARTY	5. NOTE PAYABLE - RELATED PARTY During the three months ended March 31, 2022, Michael Feinsod, the Company’s chief executive officer, was repaid $2,500.

Convertible Note Payable

Convertible Note Payable	3 Months Ended
	Mar. 31, 2022
Convertible Debenture Related Party [Abstract]
CONVERTIBLE NOTE PAYABLE	6. CONVERTIBLE NOTE PAYABLE On December 24, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which the Company issued and sold to the investor an original issue discount convertible debenture in the principal amount of $500,000, for a purchase price of $300,000. The Company also issued to the investor 5,000,000 shares of common stock valued at $55,000 ($0.005 per share). The Company recorded beneficial conversion of $245,000 due to the conversion feature. The debenture could not be converted to common stock to the extent such conversion would result in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock. The debenture had an original maturity date of April 30, 2020 and was convertible into shares of common stock of the Company at an initial conversion price of $0.001, except that, if the Company failed to repay the debenture upon maturity, the conversion price would be reduced to $0.0004 (subject to adjustment for stock splits, stock dividends, and similar transactions) and the debenture would bear interest at the rate of 9% per year. The Company’s obligation to repay the debenture upon maturity was initially secured by a security interest in the Company’s inventory pursuant to a security agreement between the Company and the investor. For the year ended August 31, 2020 the Company recorded amortization of debt discount of $500,000. A portion of the debenture was subsequently sold by the original purchaser to a third party. On April 23, 2020, the Company entered into an amendment to the security agreement with the holders of the debentures. Pursuant to the security agreement amendment, the collateral under the security agreement was amended to be the Company’s URLs. The Company also entered into six amendments to the debentures, including to increase the conversion price to $0.05, and to extend the maturity date, including an amendment entered into on August 2, 2021, to extend the maturity date to August 31, 2021. In September 2021, a debenture holder converted $100,000 into 2,000,000 shares of common stock at a price of $0.05 per share. As of March 31, 2022, there is no convertible debt outstanding. On October 28, 2021, in connection with a stock purchase agreement, the Debenture with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder. In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names valued at $32,748 and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company, and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. The Company recorded a gain on the extinguishment of debt $292,252.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
LEASES	7. LEASES In connection with the Wonderleaf Purchase Agreement, Bespoke Colorado entered into a lease agreement (the “Lease”) with WL Holdings, Ltd. (“WL Holdings”) Pursuant to the Lease, Bespoke Colorado will lease from WL Holdings certain commercial space in Aurora, Colorado, where WonderLeaf’s business has been located, commencing upon signing of the Lease and Wonderleaf Purchase Agreement, for a term of five years, which Bespoke Colorado will have an option to renew for an additional five years. Monthly rent under the Lease will start at $6,000. The Lease grants the Company an option to purchase the property for $600,000. The Company has not decided whether it will exercise either option. Supplemental balance sheet information related to leases was as follows: March 31, Operating Leases Classification 2022 Right-of-use assets Right of use assets $ 324,035 Current lease liabilities Current operating lease liabilities 61,279 Non-current lease liabilities Long-term operating lease liabilities 264,219 Total lease liabilities $ 325,498 Lease term and discount rate were as follows: December 31, 2021 Weighted average remaining lease term (years) 4.67 Weighted average discount rate 4 % The component of lease costs was as follows: Three months March 31, 2022 Operating lease cost $ 19,098 Variable lease cost (1) 1,050 Total lease costs $ 20,148 (1) Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate. Supplemental disclosures of cash flow information related to leases were as follows: March 31, 2022 Cash paid for operating lease liabilities $ 18,000 Maturities of lease liabilities were as follows as of December 31, 2021: Operating Leases 2022 $ 54,300 2023 75,600 2024 75,915 2025 79,380 2026 72,765 Thereafter - Total undiscounted lease payments 357,960 Less: Present value discount (32,462 ) Total Present value of lease liabilities $ 325,498

Equity

Equity	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
EQUITY	8. EQUITY Common Stock and Preferred Stock As of March 31, 2022 and December 31, 2021, the Company’s authorized capital stock consists of 3,000,000,000 shares of common stock, par value $0.001, and 50,000,000 shares of preferred stock, par value $0.001. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. The Company’s Certificate of Designation of Series B Preferred Stock was withdrawn by the Company on June 30, 2020. 1 share of preferred stock is designated Series C Preferred Stock and is issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to the stated value. Upon payment of the redemption price by the Company, the Series C Preferred Stock will revert to the status of authorized but unissued preferred stock. On October 28, 2021, the Company entered into a stock purchase agreement with Danil Pollack (the Company’s then-chief executive officer), and Infinity Management, LLC (“Infinity”). Pursuant to the purchase agreement, upon the closing thereof on November 19, 2021, Mr. Pollack sold to Infinity, 50,000,000 shares of common stock of the Company and one share of Series C preferred stock of the Company for cash consideration of $40,000. The Series C Preferred Stock Infinity acquired represents 51% of the voting power of the Company’s capital stock, and therefore the transaction resulted in a change-in-control of the Company. The purchase agreement further provided for Infinity to make a capital contribution to the Company of $4,792 to cover payment of the amounts due to certain creditors of the Company, as set forth in the purchase agreement. The amount was paid on January 18, 2022. On December 2, 2021, Bespoke Colorado, a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement, As of the date of filing the Company has not closed on the transaction. On December 14, 2021, the board of directors of the Company adopted the Company’s 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to which up to an aggregate of 300,000,000 shares of common stock are available for issuance. Awards under the plan may include options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, restricted stock units, performance share awards, or other equity-based awards, each as defined under the 2021 Plan. Options awarded under the 2021 Plan are to have an exercise price of not less than 100% of the fair market value of the common stock on the grant date and a term of not more than ten years from the option grant date. On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock valued at $675,000 ($0.03 per share), which will vest one year from the date of grant. During the three months ended March 31, 2022 the Company recorded $166,438 of expenses associated with the stock based compensation. On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock valued at $1,350,000 ($0.03 per share), which will vest one year from the date of grant. During the three months ended March 31, 2022 the Company recorded $332,877 of expenses associated with the stock based compensation. During the three months ended March 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 39,450,000 shares of common stock and warrants to purchase an aggregate of 9,862,500 shares of common stock, for an aggregate purchase price of $197,250. The warrants have a term of one year and an exercise price of $0.05. Warrants During the three months ended March 31, 2022, the Company entered into and closed securities purchase agreements with investors pursuant to which the Company issued and sold to the investors an aggregate of 39,450,000 shares of common stock and warrants to purchase an aggregate of 9,862,500 shares of common stock, for an aggregate purchase price of $197,250. The warrants have a term of one year and an exercise price of $0.05. The following table summarizes the warrant activities during the three months ended March 31, 2022: Number of Weighted- Weighted- Outstanding at December 31, 2021 15,500,000 $ 0.14 1.15 years Granted 9,862,500 0.05 1.0 years Canceled or expired (30,000 ) 0.40 Exercised - - Outstanding at March 31, 2022 25,332,500 $ 0.11 0.90 years Exercisable at March 31, 2022 25,332,500 $ 0.11 0.90 years Intrinsic value at March 31, 2022 $ - Options On December 14, 2021, the Company entered into an employment agreement with Hunter Garth, wherein the Company granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The options were valued at $450,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $67,797 of expenses associated with the vesting of these stock options. (See notes 9 and 10). On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, wherein the Company granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. The Options were valued at $900,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $135,594 of expenses associated with the vesting of these stock options. (See notes 9 and 10). On December 14, 2021 Company issued to a consultant options to purchase 1,000,000 shares of common stock at an exercise price of $0.03. The options vest over a period of 3 months and have life of 10 years. The options were valued at $30,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $24,900 of expenses associated with the vesting of these stock options. The following table summarizes the option activities during the three months ended March 31, 2022: Number of Weighted- Weighted- Outstanding at December 31, 2021 46,072,874 $ 0.06 9.95 years Granted - - Canceled or expired - - Exercised - - Outstanding at March 31, 2022 46,072,874 $ 0.06 9.70 years Exercisable at March 31, 2022 1,072,874 $ 0.03 9.44 years Intrinsic value at March 31, 2022 $ -

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	9. RELATED PARTY TRANSACTIONS On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. Pursuant to the employment agreement, Mr. Pollack agreed to serve as the Company’s chief executive officer and president for a period of one year, which term would renew automatically for successive one year terms, subject to the right of either party to terminate the agreement at any time upon written notice. Mr. Pollack was granted the right, for a period of six months, to purchase up to 100,000,000 shares of common stock of the Company for a purchase price of $0.001 per share. On September 30, 2020, the Company entered into an amendment to the Company’s employment agreement, dated April 22, 2020, with Danil Pollack, the Company’s then-chief executive officer. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $48,000. On April 27, 2021, the Company entered into an amendment to the Company’s employment agreement with Mr. Pollack. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $66,000 effective April 1, 2021. The Company could also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. On November 2, 2021, effective July 1, 2021 Mr. Pollack waived all compensation owed to him by the Company as of such date through the date of his resignation as the Company’s chief executive officer. Mr. Pollack elected to forgive $11,000 of salary during four months ended December 31, 2021, and the amount was recorded as a capital contribution. On October 28, 2021, the Company entered into a stock purchase agreement with Danil Pollack, and Infinity Management, LLC. Pursuant to the purchase agreement, upon the closing thereof on November 19, 2021, Mr. Pollack sold to Infinity, 50,000,000 shares of the common stock of the Company and one share of Series C preferred stock of the Company for cash consideration of $40,000. The Series C Preferred Stock Infinity acquired represents 51% of the voting power of the Company’s capital stock, and therefore the transaction resulted in a change-in-control of the Company. The purchase agreement further provided for Infinity to make a capital contribution to the Company of $4,792 to cover payment of the amounts due to certain creditors of the Company, as set forth in the purchase agreement. The amount was paid on January 18, 2022. In connection with the purchase agreement, and effective upon the closing thereunder, Mr. Michael Feinsod, the managing member of Infinity, was appointed as the chief executive officer and chairman of the board of directors of the Company, Mr. Hunter Garth was appointed as a director, as well as chief strategy officer of the Company, and Mr. Pollack resigned from all positions with the Company, including as president, CEO, chief financial officer and director of the Company. On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10). On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10). During the three months ended March 31, 2022, Michael Feinsod, the Company’s chief executive officer, was repaid $2,500.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES On April 21, 2020, Danil Pollack was appointed president, chief executive officer, and chief financial officer of the Company. In connection with Mr. Pollack’s appointment, the Company entered into an employment agreement with Mr. Pollack. On September 30, 2020, the Company entered into an amendment to the employment agreement. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $48,000. On April 27, 2021, the Company entered into an amendment to the Company’s employment agreement with Mr. Pollack. Pursuant to the amendment, the Company agreed to pay Mr. Pollack an annual salary of $66,000 effective April 1, 2021. The Company may also in its discretion pay additional compensation to Mr. Pollack at any time as a bonus. Mr. Pollack elected to forgive $11,000 of salary during four months ended December 31, 2021; the amount was recorded as a capital contribution. Mr. Pollack resigned on November 19, 2021. In connection with the purchase agreement, a convertible debenture with an original issue date of December 24, 2019, as amended by Amendment No. 1 thereto, dated May 28, 2020, Amendment No. 2 thereto, dated August 21, 2020, Amendment No. 3 thereto, dated December 10, 2020, Amendment No. 4 thereto, dated January 15, 2021, Amendment No. 5 thereto, dated April 2, 2021, and Amendment No. 6 thereto, dated August 2, 2021 (as amended, the “Debenture”) with an original principal amount of approximately $400,000 was terminated, and all amounts due and payable thereunder forgiven pursuant to a cancellation and satisfaction of debenture agreement entered into between the Company and the Debenture holder (the “Debt Cancellation Agreement”). In exchange for cancellation of the debt owed under the Debenture, the Company transferred to the holder certain domain names and agreed to pay the holder, beginning December 1, 2021, and on a monthly basis through August 31, 2022, 40% of the operating profit generated from sale of the existing CBD inventory of the Company (the “Inventory Earn Out”), and on August 31, 2022, to make a final payment equal to an amount of $75,000 minus the total of the monthly payments made under the Inventory Earn Out. (See notes 3 and 6). On December 14, 2021, the Company entered into an employment agreement with Hunter Garth. Pursuant to the employment agreement, Mr. Garth will serve as the Company’s president and will receive a base monthly salary of $8,000. The Company also granted to Mr. Garth, pursuant to the Company’s 2021 Equity Incentive Plan, 22,500,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 15,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Garth is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10). On December 14, 2021, the Company entered into an employment agreement with Michael Feinsod, the Company’s chief executive officer and chairman. Pursuant to the employment agreement, Mr. Feinsod will continue to serve as the Company’s chief executive officer and chairman and will receive a base monthly salary of $10,000. The Company also granted to Mr. Feinsod, pursuant to the Company’s 2021 Equity Incentive Plan, 45,000,000 shares of restricted common stock, which will vest one year from the date of grant, and ten-year options to purchase 30,000,000 shares of common stock at an exercise price of $0.06 (representing a 120% premium over the closing price of the common stock on December 13, 2021). One-third of the options will vest on each yearly anniversary of the date of grant. In the event that Mr. Feinsod is terminated without cause or resigns with good reason (each as defined in the employment agreement), he will be entitled to his monthly base salary for twelve months following such termination. (See notes 8 and 10).

Major Customers

Major Customers	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
MAJOR CUSTOMERS	11. MAJOR CUSTOMERS At March 31, 2022 and December 31, 2021, no individual customer amounted to over 10% of total accounts receivable. During the three months ended March 31, 2022, one individual customer amounted to over 10% of total sales. During the three months ended March 31, 2021, no individual customer amounted to over 10% of total sales.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS On April 5, 2022, the Company issued and sold to an investor in a private placement 10,000,000 shares of common stock and warrants to purchase 2,500,000 shares of common stock with a term of one year and an exercise price of $0.05, for a purchase price of $50,000. On May 16, 2022, the Company issued and sold to an investor in a private placement 1,000,000 shares of common stock and warrants to purchase 250,000 shares of common stock with a term of one year and an exercise price of $0.05, for a purchase price of $5,000.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Nature of Business Operations	Nature of Business Operations Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on selling its proprietary line of specially-formulated, premium quality, hemp-derived CBD products. In November 2021, new management of the Company was appointed and the Company began to focus on other complimentary lines of business to its CBD offerings. Under our new management team, we plan to expand the Company’s focus to regulated cannabis markets in the United States. On December 2, 2021, Bespoke Extracts Colorado, LLC (“Bespoke Colorado”), a newly formed wholly-owned subsidiary of the Company entered into an asset purchase agreement with WonderLeaf, LLC (“WonderLeaf”), and on December 7, 2021, Bespoke Colorado and WonderLeaf entered into an amendment to such asset purchase agreement (as amended, the “WonderLeaf Purchase Agreement”). Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the WonderLeaf Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement. As of the date of filing the Company has not closed on the transaction.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022 may not necessarily be indicative of the results that may be expected for the year ended December 31, 2022. For further information, refer to the Company’s financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2021 and the Transition Report on Form 10Q-T for the transition period from September 1, 2021 to December 31, 2021. On February 2, 2022, the Company changed its fiscal year from August 31 to December 31. Certain prior period amounts have been reclassified to conform to the current period presentation.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated unaudited financial statements include the accounts of Bespoke Extracts, Inc., and its wholly owned subsidiary Bespoke Extracts Colorado, LLC. All inter-company balances have been eliminated.
Going Concern	Going Concern The accompanying condensed consolidated unaudited financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit as of and for the three months ended March 31, 2022. This raises substantial doubt about our ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed. Further, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. If additional financing is not available or is not available on acceptable terms, we will have to curtail or cease our operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence. These financial statements do not include any adjustments that might arise from this uncertainty.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Significant estimates include the assumption used in the valuation of equity-based transactions, valuation of intangible assets, allowance for doubtful accounts and inventory valuation and reserves. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At March 31, 2022 and December 31, 2021, the Company did not have any cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of cash, accounts receivable, prepaid expenses, inventory and other assets, accounts payable, accrued liabilities, note payable and convertible note payable approximate their fair values as of March 31, 2022 and December 31, 2021, respectively, because of their short-term natures and the Company’s borrowing rate of interest.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense. The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At March 31, 2022 and December 31, 2021, the Company has recorded an allowance for doubtful accounts of $0 and $0, respectively. At March 31, 2022 and December 31, 2021 included in the accounts receivable is the merchant holdback receivable balance of $3,636 and $3,636, respectively which will be remitted to the Company in the future.
Advances to WonderLeaf	Advances to WonderLeaf During the three months ended March 31, 2022 the Company advanced WonderLeaf $6,443 to cover operating expenses. The amounts are repayable upon demand.
Inventory	Inventory Inventories are stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of March 31, 2022 and December 31, 2021, inventory amounted to $46,470 and $46,825, respectively, which consisted of finished goods of $43,219 and $43,574, and raw materials of $3,251 and $3,251 net of reserves, respectively. As of March 31, 2022 and December 31, 2021 inventory reserves were $33,476 and $33,476, respectively.
Revenue Recognition	Revenue Recognition We account for revenue in accordance with the Financial Accounting Standards Board (“FASB”) Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 30 day return policy on sales.
Stock Based Compensation	Stock Based Compensation Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable, and in accordance with FASB ASC 718 , Compensation-Stock Compensation,
Net Income / (Loss) per Share	Net Income / (Loss) per Share Basic income / (loss) per share amounts are computed based on net income / (loss) divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 25,333,500 warrants and 46,072,874 options is anti-dilutive for the three months ended March 31, 2022 as they are not in the money. The effect of 3,000,000 warrants and 0 options, as well as 500,000,000 shares issuable upon the conversion of a convertible note, is anti-dilutive for the three months ended March 31, 2021.
Recent Accounting Pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date.
Income Taxes	Income Taxes We utilize the asset and liability method of accounting for income taxes. We recognize deferred tax liabilities or assets for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. We regularly assess the likelihood that our deferred tax assets will be recovered from future taxable income. We consider projected future taxable income and ongoing tax planning strategies in assessing the amount of the valuation allowance necessary to offset our deferred tax assets that will not be recoverable. We have recorded and continue to carry a full valuation allowance against our gross deferred tax assets that will not reverse against deferred tax liabilities within the scheduled reversal period. If we determine in the future that it is more likely than not that we will realize all or a portion of our deferred tax assets, we will adjust our valuation allowance in the period we make the determination. We expect to provide a full valuation allowance on our future tax benefits until we can sustain a level of profitability that demonstrates our ability to realize these assets.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of supplemental balance sheet information	March 31, Operating Leases Classification 2022 Right-of-use assets Right of use assets $ 324,035 Current lease liabilities Current operating lease liabilities 61,279 Non-current lease liabilities Long-term operating lease liabilities 264,219 Total lease liabilities $ 325,498
Schedule of lease term and discount rate	December 31, 2021 Weighted average remaining lease term (years) 4.67 Weighted average discount rate 4 %
Schedule of lease costs	Three months March 31, 2022 Operating lease cost $ 19,098 Variable lease cost (1) 1,050 Total lease costs $ 20,148 (1) Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate.
Schedule of supplemental disclosures of cash flow	March 31, 2022 Cash paid for operating lease liabilities $ 18,000
Schedule of maturities of lease liabilities	Operating Leases 2022 $ 54,300 2023 75,600 2024 75,915 2025 79,380 2026 72,765 Thereafter - Total undiscounted lease payments 357,960 Less: Present value discount (32,462 ) Total Present value of lease liabilities $ 325,498

Equity (Tables)

Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Schedule of warrants	Number of Weighted- Weighted- Outstanding at December 31, 2021 15,500,000 $ 0.14 1.15 years Granted 9,862,500 0.05 1.0 years Canceled or expired (30,000 ) 0.40 Exercised - - Outstanding at March 31, 2022 25,332,500 $ 0.11 0.90 years Exercisable at March 31, 2022 25,332,500 $ 0.11 0.90 years Intrinsic value at March 31, 2022 $ -
Schedule of stock options	Number of Weighted- Weighted- Outstanding at December 31, 2021 46,072,874 $ 0.06 9.95 years Granted - - Canceled or expired - - Exercised - - Outstanding at March 31, 2022 46,072,874 $ 0.06 9.70 years Exercisable at March 31, 2022 1,072,874 $ 0.03 9.44 years Intrinsic value at March 31, 2022 $ -

Nature of Operations, Signifi_2

Nature of Operations, Significant Accounting Policies and Going Concern (Details) - USD ($)	Dec. 02, 2021	Mar. 31, 2022	Dec. 31, 2021
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Agreement purchase price	$ 225,000
Common stock including shares issuable (in Shares)	2,500,000
Additional common stock	$ 150,000
Price per share (in Dollars per share)	$ 0.04
Inventory purchase price, percentage	90.00%
Allowance for doubtful accounts		$ 0	$ 0
Accounts receivable		3,636	3,636
Operating expenses		6,443
Inventory		46,470	46,825
Inventory finished goods		43,219	43,574
Raw material, net reserve		3,251	3,251
Inventory reserves		$ 33,476	$ 33,476
Anti-dilutive options (in Shares)		46,072,874
Shares issuable conversion of a convertible note (in Shares)		500,000,000
Common Stock [Member]
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Price per share (in Dollars per share)	$ 0.02
Warrant [Member]
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Shares warrants (in Shares)		25,333,500
Anti-dilutive shares of warrants and options (in Shares)		3,000,000
Options [Member]
Nature of Operations, Significant Accounting Policies and Going Concern (Details) [Line Items]
Anti-dilutive shares of warrants and options (in Shares)		0

Asset Purchase Agreement (Detai

Asset Purchase Agreement (Details) - USD ($)	3 Months Ended		12 Months Ended	24 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Aug. 31, 2020	Aug. 31, 2021	Feb. 21, 2017
Asset Purchase Agreement (Details) [Line Items]
Asset purchase agreement total					$ 20,185
Number of common stock shares (in Shares)					200,000
Common stock value					$ 30,000
Transferred value			$ 5,282
Impairment of unrelated party			289
Impaired of leaving balance			$ 44,614
Amortized over period			15 years
Amortization expense				$ 3,244
Transferred amount	$ 32,748
Asset Purchase Agreement [Member]
Asset Purchase Agreement (Details) [Line Items]
Amortization expense	0	$ 811
Impairment leaving balance				$ 289
Original principal amount	$ 400,000

Inventory Earn-Out (Details)

Inventory Earn-Out (Details) - Forecast [Member]	Aug. 31, 2022USD ($)
Inventory Earn-Out (Details) [Line Items]
Operating profit, sale percentage	40.00%
Inventory earn out	$ 75,000

Note Receivable (Details)

Note Receivable (Details) - USD ($)	Feb. 08, 2022	Jan. 19, 2022	Mar. 31, 2022
Note Receivable (Details) [Line Items]
Promissory note	$ 10,000	$ 10,000
Annual interest rate	5.00%	5.00%
Maturity date	Feb. 8, 2023	Jan. 18, 2023
WonderLeaf [Member]
Note Receivable (Details) [Line Items]
Accrued interest			$ 111
WonderLeaf One [Member]
Note Receivable (Details) [Line Items]
Accrued interest			$ 70

Note Payable - Related Party (D

Note Payable - Related Party (Details)	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
Repaid	$ 2,500

Convertible Note Payable (Detai

Convertible Note Payable (Details) - USD ($)	Dec. 02, 2021	Oct. 28, 2021	Sep. 30, 2021	Dec. 24, 2019	Aug. 31, 2022	Aug. 31, 2020	Aug. 02, 2021
Convertible Note Payable (Details) [Line Items]
Principal amount				$ 500,000
Purchase amount				$ 300,000
Issuance of common stock, shares (in Shares)				5,000,000
Common stock value				$ 55,000
Common stock per share price (in Dollars per share)				$ 0.005
Beneficial conversion feature				$ 245,000
Company outstanding percentage				4.99%
Conversion price (in Dollars per share)				$ 0.001			$ 0.05
Conversion price reduced per share (in Dollars per share)				$ 0.0004
Percentage of interest rate				9.00%
Debenture holder converted amount			$ 100,000
Converted to shares of common stock (in Shares)			2,000,000
Common stock price per share (in Dollars per share)			$ 0.05
Principal amount		$ 400,000
Debenture holder amount	$ 32,748
Forecast [Member]
Convertible Note Payable (Details) [Line Items]
Percentage of operating profit generated					40.00%
Total of the monthly payments					$ 75,000
Gain (Loss) on extinguishment of debt					$ 292,252
Securities Purchase Agreement [Member]
Convertible Note Payable (Details) [Line Items]
Amortization of debt discount						$ 500,000

Leases (Details)

Leases (Details)	3 Months Ended
	Mar. 31, 2022USD ($)
Leases [Abstract]
Lease term	5 years
Renew for an additional term	5 years
Rent amount	$ 6,000
Purchase of property	$ 600,000

Leases (Details) - Schedule of

Leases (Details) - Schedule of supplemental balance sheet information	3 Months Ended
	Mar. 31, 2022USD ($)
Schedule of supplemental balance sheet information [Abstract]
Right-of-use assets, Classification	Right of use assets
Right-of-use assets	$ 324,035
Current lease liabilities, Classification	Current operating lease liabilities
Current lease liabilities	$ 61,279
Non-current lease liabilities, Classification	Long-term operating lease liabilities
Non-current lease liabilities	$ 264,219
Total lease liabilities	$ 325,498

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of lease term and discount rate	Dec. 31, 2021
Schedule of lease term and discount rate [Abstract]
Weighted average remaining lease term (years)	4 years 8 months 1 day
Weighted average discount rate	4.00%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of lease costs	3 Months Ended
	Mar. 31, 2022USD ($)
Schedule of lease costs [Abstract]
Operating lease cost	$ 19,098
Variable lease cost	1,050	[1]
Total lease costs	$ 20,148
[1]	Variable lease cost primarily relates to common area maintenance, property taxes and insurance on leased real estate.

Leases (Details) - Schedule o_4

Leases (Details) - Schedule of supplemental disclosures of cash flow	3 Months Ended
	Mar. 31, 2022USD ($)
Schedule of supplemental disclosures of cash flow [Abstract]
Cash paid for operating lease liabilities	$ 18,000

Leases (Details) - Schedule o_5

Leases (Details) - Schedule of maturities of lease liabilities	Mar. 31, 2022USD ($)
Schedule of maturities of lease liabilities [Abstract]
2022	$ 54,300
2023	75,600
2024	75,915
2025	79,380
2026	72,765
Thereafter
Total undiscounted lease payments	357,960
Less: Present value discount	(32,462)
Total Present value of lease liabilities	$ 325,498

Equity (Details)

Equity (Details) - USD ($)	Dec. 14, 2021	Dec. 13, 2021	Dec. 07, 2021	Oct. 28, 2021	Mar. 31, 2022	Dec. 31, 2021
Equity (Details) [Line Items]
Common stock, shares authorized					3,000,000,000	3,000,000,000
Common stock, par value					$ 0.001	$ 0.001
Preferred stock, shares authorized					50,000,000	50,000,000
Preferred stock, par value					$ 0.001	$ 0.001
Preferred stock designated, shares issued					1	1
Preferred stock designated, shares outstanding					1	1
Common stock, description	Company issued to a consultant options to purchase 1,000,000 shares of common stock at an exercise price of $0.03. The options vest over a period of 3 months and have life of 10 years. The options were valued at $30,000 using a Black-Scholes pricing model. During the three months ended March 31, 2022 the Company recorded $24,900 of expenses associated with the vesting of these stock options.
Purchase agreement, description			Pursuant to the Wonderleaf Purchase Agreement, Bespoke Colorado agreed to purchase from WonderLeaf, and WonderLeaf agreed to sell to Bespoke Colorado, certain assets of WonderLeaf, including a license to manufacture marijuana-infused products, existing inventory, and extraction equipment and ancillary items, all as further set forth in the Wonderleaf Purchase Agreement, for a purchase price of $225,000, to be paid in shares of common stock of the Company (including 2,500,000 shares issuable, and to be held in escrow, upon execution of the Purchase Agreement, and an additional $150,000 of common stock that will be valued based on the volume weighted average price of the common stock, subject to a floor of $0.02 per share and a ceiling of $0.04 per share), provided that, the purchase price for the inventory will be 90% of the wholesale value of the regulated marijuana portion of the inventory and the packaging corresponding thereto set forth on the inventory accounting statement to be prepared pursuant to the Wonderleaf Purchase Agreement, As of the date of filing the Company has not closed on the transaction.
Sale of stock, number of shares issued					1
Base monthly salary	$ 8,000
Common stock value					$ 0.05
Shares sold to investors					39,450,000
Warrant to purchase					9,862,500
Warrant purchase price					$ 197,250
Warrant [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued					1
Option grant date term					10 months 24 days
Common stock value					$ 0.05
Shares sold to investors					39,450,000
Warrant to purchase					9,862,500
Warrant purchase price					$ 197,250
Exercise price					$ 0.11
2021 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued	300,000,000
Fair market value of common stock, percentage	100.00%
Option grant date term	10 years
Equity Option [Member]
Equity (Details) [Line Items]
Exercise price					$ 0.03
Series A Preferred Stock [Member]
Equity (Details) [Line Items]
Preferred stock, shares designated					1,000
Series C Preferred Stock [Member]
Equity (Details) [Line Items]
Preferred stock, par value					$ 0.001	$ 0.001
Preferred stock, shares designated					1	1
Preferred stock designated, shares issued					1	1
Preferred stock designated, shares outstanding					1	1
Preferred stock stated value					$ 24,000
Voting power of percentage					51.00%
Hunter Garth [Member]
Equity (Details) [Line Items]
Expenses associated with vesting stock options					$ 166,438
Hunter Garth [Member] | 2021 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Vesting period	1 year
Hunter Garth [Member] | Equity Option [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued	15,000,000
Expenses associated with vesting stock options					67,797
Exercise price	$ 0.06
Premium over closing price, percentage		120.00%
Options were valued					450,000
Michael Feinsod [Member]
Equity (Details) [Line Items]
Base monthly salary					10,000
Expenses associated with vesting stock options					332,877
Michael Feinsod [Member] | 2021 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued	30,000,000
Vesting period	1 year
Expenses associated with vesting stock options					$ 135,594
Exercise price	$ 0.06
Premium over closing price, percentage		120.00%
Options were valued	$ 900,000
Restricted Stock [Member] | Hunter Garth [Member] | 2021 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued	22,500,000
Common stock value	$ 675,000
Common stock value, per share	$ 0.03
Restricted Stock [Member] | Michael Feinsod [Member] | 2021 Equity Incentive Plan [Member]
Equity (Details) [Line Items]
Sale of stock, number of shares issued	45,000,000
Common stock value	$ 1,350,000
Common stock value, per share	$ 0.03
Chief Executive Officer [Member]
Equity (Details) [Line Items]
Voting power of percentage				51.00%
Common stock, description				Pursuant to the purchase agreement, upon the closing thereof on November 19, 2021, Mr. Pollack sold to Infinity, 50,000,000 shares of common stock of the Company and one share of Series C preferred stock of the Company for cash consideration of $40,000.
Infinity capital cover payment				$ 4,792

Equity (Details) - Schedule of

Equity (Details) - Schedule of warrants - Warrants [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Warrants, Outstanding Beginning balance (in Shares) | shares	15,500,000
Weighted-Average Price Per Share, Outstanding Beginning balance	$ 0.14
Weighted- Average Remaining Life, Outstanding Beginning years	1 year 1 month 24 days
Number of Warrants, Granted (in Shares) | shares	9,862,500
Weighted-Average Price Per Share, Granted	$ 0.05
Weighted- Average Remaining Life, Granted	1 year
Number of Warrants, Cancelled or expired (in Shares) | shares	(30,000)
Weighted-Average Price Per Share, Cancelled or expired	$ 0.4
Number of Warrants, Exercised (in Shares) | shares
Weighted-Average Price Per Share, Exercised / Exchanged
Number of Warrants, Outstanding Ending balance (in Shares) | shares	25,332,500
Weighted-Average Price Per Share, Outstanding Ending balance	$ 0.11
Weighted- Average Remaining Life, Outstanding Ending years	10 months 24 days
Number of Warrants, Exercisable (in Shares) | shares	25,332,500
Weighted-Average Price Per Share, Exercisable	$ 0.11
Weighted- Average Remaining Life, Exercisable	10 months 24 days
Weighted-Average Price Per Share Intrinsic value

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of stock options - Options [Member]	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Equity (Details) - Schedule of stock options [Line Items]
Number of Options, Outstanding Beginning balance (in Shares) | shares	46,072,874
Weighted-Average Price Per Share, Outstanding Beginning balance	$ 0.06
Weighted- Average Remaining Life, Outstanding Beginning yeas	9 years 11 months 12 days
Number of Options, Granted (in Shares) | shares
Weighted-Average Price Per Share, Granted
Weighted- Average Remaining Life, Granted
Number of Options, Canceled or expired (in Shares) | shares
Weighted-Average Price Per Share, Canceled or expired
Number of Options, Exercised (in Shares) | shares
Weighted-Average Price Per Share, Exercised
Number of Options, Outstanding Ending balance (in Shares) | shares	46,072,874
Weighted-Average Price Per Share, Outstanding Ending balance	$ 0.06
Weighted- Average Remaining Life, Outstanding ending years	9 years 8 months 12 days
Number of Options, Exercisable (in Shares) | shares	1,072,874
Weighted-Average Price Per Share, Exercisable	$ 0.03
Weighted- Average Remaining Life, Exercisable	9 years 5 months 8 days
Weighted-Average Price Per Share Intrinsic value

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	Dec. 14, 2021	Dec. 13, 2021	Apr. 01, 2021	Nov. 19, 2021	Sep. 30, 2020	Apr. 21, 2020	Mar. 31, 2022	Dec. 31, 2021
Related Party Transactions (Details) [Line Items]
Shares of common stock						100,000,000
Purchase price per share (in Dollars per share)						$ 0.001
Salary (in Dollars)	$ 8,000
Cash consideration (in Dollars)				$ 40,000
Capital contribution (in Dollars)							$ 4,792
Series C Preferred Stock [Member]
Related Party Transactions (Details) [Line Items]
Common stock shares issued				1
Percentage of voting power				51.00%
Mr. Pollack [Member]
Related Party Transactions (Details) [Line Items]
Shares of common stock				50,000,000
Salary (in Dollars)			$ 66,000		$ 48,000			$ 11,000
Hunter Garth [Member]
Related Party Transactions (Details) [Line Items]
Salary (in Dollars)	$ 8,000
Mr. Garth [Member]
Related Party Transactions (Details) [Line Items]
Shares of common stock	15,000,000
Exercise price (in Dollars per share)	$ 0.06
Common stock percentage		120.00%
Mr. Garth [Member] | 2021 Equity Incentive Plan [Member]
Related Party Transactions (Details) [Line Items]
Restricted common stock shares	22,500,000
Vested term	1 year
Michael Feinsod [Member]
Related Party Transactions (Details) [Line Items]
Salary (in Dollars)	$ 10,000
Mr. Feinsod [Member]
Related Party Transactions (Details) [Line Items]
Shares of common stock	30,000,000
Exercise price (in Dollars per share)	$ 0.06
Common stock percentage		120.00%
Mr. Feinsod [Member] | 2021 Equity Incentive Plan [Member]
Related Party Transactions (Details) [Line Items]
Shares of common stock	45,000,000
Vested term	1 year
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Related party term						1 year
Related party renew terms						1 year
Shares of loaned							2,500

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Dec. 14, 2021	Dec. 13, 2021	Aug. 02, 2021	Apr. 27, 2021	Aug. 31, 2022	Sep. 30, 2020	Dec. 31, 2021
Commitments and Contingencies (Details) [Line Items]
Mr. Pollack an annual salary				$ 66,000
Mr. Pollack forgive salary							$ 11,000
Principal amount			$ 400,000
Executive officer salary	$ 8,000
Common stock ,options to purchase (in Shares)	30,000,000
Exercise price (in Dollars per share)	$ 0.06
Premium percentage		120.00%
Equity Incentive Plan [Member]
Commitments and Contingencies (Details) [Line Items]
Restricted common stock (in Shares)	22,500,000
Common Stock [Member]
Commitments and Contingencies (Details) [Line Items]
Exercise price (in Dollars per share)	$ 0.06
Premium percentage		120.00%
Restricted common stock [Member]
Commitments and Contingencies (Details) [Line Items]
Restricted common stock (in Shares)	45,000,000
Grant [Member]
Commitments and Contingencies (Details) [Line Items]
Common stock ,options to purchase (in Shares)	15,000,000
Forecast [Member]
Commitments and Contingencies (Details) [Line Items]
Operating profit, percentage					40.00%
Final payment of inventory earn out					$ 75,000
Securities Purchase Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Mr. Pollack an annual salary						$ 48,000
Chief Executive Officer [Member]
Commitments and Contingencies (Details) [Line Items]
Executive officer salary	$ 10,000

Major Customers (Details)

Major Customers (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Total accounts receivable in percentage	10.00%		10.00%
Total sales in percentage	10.00%	10.00%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Apr. 05, 2022$ / sharesshares
Subsequent Events (Details) [Line Items]
Common stock, term	1 year
Exercise price per share (in Dollars per share) | $ / shares	$ 0.05
Purchase price	50,000
Private Placement [Member]
Subsequent Events (Details) [Line Items]
Common stock shares	10,000,000
Warrant [Member]
Subsequent Events (Details) [Line Items]
Common stock shares	2,500,000